Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

29.05USD
14 Dec 2018
Change (% chg)

$-0.99 (-3.30%)
Prev Close
$30.04
Open
$29.67
Day's High
$29.95
Day's Low
$28.97
Volume
1,340,239
Avg. Vol
1,676,640
52-wk High
$47.81
52-wk Low
$28.97

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 31.22 31.13 34.39
EPS (TTM): 1.23 -- --
ROI: 2.39 15.55 14.96
ROE: 5.71 16.92 16.52

South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

13 Dec 2018

UPDATE 1-South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG, Dec 13 Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

13 Dec 2018

Mylan says Sanofi loses Lantus insulin patent claims

U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

13 Dec 2018

UPDATE 2-Mylan says Sanofi loses Lantus insulin patent claims

Dec 13 U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus.

13 Dec 2018

Mylan says patent office cancels Sanofi's Lantus patents

Dec 13 Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker.

13 Dec 2018

Mylan to recall all batches of blood pressure medicine valsartan in U.S.

Mylan NV said on Tuesday it is expanding a nationwide voluntary recall of its blood pressure medicine valsartan to include all lots, two weeks after it recalled select batches.

04 Dec 2018

UPDATE 3-Mylan to recall all batches of blood pressure medicine valsartan in U.S.

Dec 4 Mylan NV said on Tuesday it is expanding a nationwide voluntary recall of its blood pressure medicine valsartan to include all lots, two weeks after it recalled select batches.

04 Dec 2018

Mylan to recall all batches of blood pressure medicine in U.S.

Dec 4 Mylan NV said on Tuesday it is issuing a nationwide voluntary recall of all lots of its blood pressure medicine valsartan, expanding a recall of select batches initiated two weeks ago.

04 Dec 2018

Teva to recall certain blood pressure medicine in U.S

Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity, the latest global recall of the medicine.

27 Nov 2018

Teva to recall certain blood pressure medicine in U.S.

Nov 27 Teva Pharmaceutical Industries Ltd is recalling certain combinations of blood pressure drug valsartan in the United States following the detection of a probable cancer-causing impurity, the latest global recall of the medicine.

27 Nov 2018

Earnings vs. Estimates